PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
- Conditions
- Non-small Cell Lung CancerUrothelial Cancer
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT03317496
- Locations
- ๐ช๐ธ
Hospital Universitario Vall d'Hebron, Barcelona, Spain
๐จ๐ฟFakultni nemocnice Olomouc, Klinika nuklearni mediciny, Olomouc, Czechia
๐ฆ๐บSt Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: MultivalentBiological: Prevnar 13Other: SalineBiological: PPSV23
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 444
- Registration Number
- NCT03313037
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
๐บ๐ธClinical Research of South Florida, Coral Gables, Florida, United States
๐บ๐ธAvail Clinical Research, LLC, DeLand, Florida, United States
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: MultivalentBiological: polysaccharideBiological: Tdap
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 511
- Registration Number
- NCT03313050
- Locations
- ๐บ๐ธ
Core Healthcare Group, Cerritos, California, United States
๐บ๐ธHeartland Research Associates, LLC, Wichita, Kansas, United States
๐บ๐ธPMG Research of Wilmington, LLC, Wilmington, North Carolina, United States
Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
- Conditions
- Hepatic Impairment
- Interventions
- Drug: PF-05221304
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03309202
- Locations
- ๐ธ๐ฐ
Univerzitnรก Nemocnica Bratislava, Bratislava, Slovakia
๐จ๐ฟPharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
๐ธ๐ฐSummit Clinical Research s.r.o., Bratislava, Slovakia
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT03309241
- Locations
- ๐บ๐ธ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
- Conditions
- Hemophilia B
- Interventions
- Biological: PF-06838435 (formerly SPK-9001)
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT03307980
- Locations
- ๐บ๐ธ
LA Center for Bleeding and Clotting Disorders - Metairie, Metairie, Louisiana, United States
๐บ๐ธTulane Lakeside Hospital, Metairie, Louisiana, United States
๐บ๐ธUniversity Medical Center New Orleans, New Orleans, Louisiana, United States
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03308110
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit, Brussels, Belgium
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT03289533
- Locations
- ๐ฏ๐ต
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
๐ฏ๐ตIizuka Hospital, Iizuka, Fukuoka, Japan
๐ฏ๐ตKindai University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
- Conditions
- Breast Neoplasms
- Interventions
- Drug: PF-06804103Drug: PF-06804103 + Palbociclib +Letrozole
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 95
- Registration Number
- NCT03284723
- Locations
- ๐บ๐ธ
UCLA Health (main campus), Los Angeles, California, United States
๐บ๐ธCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
๐บ๐ธNorthside Hospital, Inc. - GCS/Macon, Macon, Georgia, United States
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: CP-690,500 5 mgDrug: CP-690,550 10 mg
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT03281304
- Locations
- ๐บ๐ธ
Clinical Applications Laboratories, Inc., San Diego, California, United States
๐บ๐ธBristol Hospital, Bristol, Connecticut, United States
๐บ๐ธConnecticut Clinical Research Institute, Bristol, Connecticut, United States